AbbVie continues to be top of the TV drug ad spenders as its immunology blockbuster Skyrizi dominates this year’s iSpot roundup. After taking the top spot again last month, the Big Pharma is running ...

The one newcomer on the list was UCB’s Bimzelx, which knocked Intra-Cellular Therapies' Caplyta out of the running as it took ...

AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.

Q2 sales rose 6.6% to $15.42 billion, beating estimates; EPS of $2.97 missed the $3.23 consensus. FY25 adjusted EPS guidance raised to $11.88–$12.08 vs estimate of $12.24. Get the strategy to turn ...

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total ...